Patients who need to take warfarin, including prothetic heart valve replacement, atrial fibrilation, deep vein thrombosis, pulmanory ebolism, stroke.
Conditions
Interventions
Total:genotype analysis
Sponsors
Institute of Clinical Pharmacology, Central South University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Chinese origin, both male and female, age unlimited; 2) Patients who need to take warfarin for 6 months and under regular PT-INR examination between January 1, 2008 and June 31, 2013. Indications include heart valve replacement, atrial fibrillation, deep vein thrombosis, pulmanory ebolism, stroke; 3) have signed informed consent, and agree to participant the project; 4) good compliance, follow up for at least 6 month.
Exclusion criteria
Exclusion criteria: 1) bad compliance, stop following up for at least 3 consecutive visits or do not take warfarin as indicated; 2) have cancer; 3) pregnant or lactating; 4) have contraindication of warfarin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| stable warfarin dosage; | — |
Countries
China
Contacts
Public ContactZhi Li
Outcome results
None listed